Research Projects & Grants

College/University

  • POEM: A PrOspective Registry of Pediatric Cellular Therapy Patients at risk for Endothelial Dysfunction, Sinusoidal Obstruction Syndrome and/or Multi-Organ Dysfunction Syndrome (MODS), Role: PI, Duke University, (11/2025 - 11/2026) Status: Approved
  • Genomic and Immunomic Mechanisms of Resistance During Daratumumab Post Stem Cell Transplantation in Patients with Poor-Risk T-Cell Lymphoblastic Lymphoma/Leukemia, Role: PD/PI, New York Medical College, (04/2024 - 09/2027) Status: Awarded
  • Outcomes in Juvenile Myelomonocytic Leukemia Patients Undergoing Hematopoietic Stem Cell Transplantation by all Donor Types and Specifically Haploidentical Donors, Role: PI, University of California, San Francisco, (08/2025) Status: Approved
  • The Role of Immunotherapy in the Treatment of Hypodiploid B-ALL and the Impact of TP53 Mutations on Outcomes, Role: PI, University of Utah, (08/2025) Status: Approved
  • A Phase II Intrapatient Open-Label Dose Escalation Trial of Defibrotide in Hematopoietic Cell Transplantation (HCT) Recipients with Sinusoidal Obstructive Syndrome (SOS) Post-HCT Associated with either Renal and/or Pulmonary Dysfunction with Either Refractory or Progressive Disease Following Defibrotide Therapy, Role: PI, New York Medical College, (05/2025 - 05/2026) Status: Approved

Default Sponsor Type

  • Genomic and Immunomic Mechanisms of Resistance During Daratumumab Post Stem Cell Transplantation in Patients with Poor-Risk T-Cell Lymphoblastic Lymphoma/Leukemia, Role: PD/PI, New York Medical College, (04/2024 - 09/2027) Status: Awarded

Federal

  • TSLP and pediatric leukemia mechanisms and treatment, Role: PI, National Cancer Institute/NIH/DHHS, (05/2025 - 05/2026) Status: Approved
  • COG AALL1631: International phase 3 trial in Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL) testing imatinib in combination with two different cytotoxic chemotherapy backbones, Role: Investigator, Children Oncology Group, (06/2025 - 06/2026) Status: Approved
  • COG AALL1131: A Phase III Randomized Trial for Newly Diagnosed High Risk B- Lymphoblastic Leukemia (B-ALL) Including a Stratum Evaluating Dasatinib (IND #73789, NSC #732517) in Patients with Ph-like Tyrosine Kinase Inhibitor (TKI) Sensitive Mutations, Role: Research Coordinator/Nurse, Children Oncology Group, (01/2026 - 01/2027) Status: Approved
  • Children's Oncology Group (COG)-AALL0932: Treatment of patients with newly diagnosed standard risk B-precursor acute lymphoblastic leukemia (ALL) or localized B-lineage lymphoblastic lymphoma (B-LLy), Role: Research Coordinator/Nurse, Children Oncology Group, (01/2026 - 01/2027) Status: Approved
  • COG AAML1531: Risk-stratified therapy for acute myeloid leukemia in Down Syndrome, Role: Investigator, Children Oncology Group, (10/2025 - 10/2026) Status: Approved
  • COG AALL1621: phase 2 study of Inotuzumab Ozogamicin (NSC# 772518, IND#133494) in children and young adults with relapsed or refractory CD22+ B-Acute Lymphoblastic Leukemia (B-ALL), Role: Investigator, Children Oncology Group, (05/2025 - 05/2026) Status: Approved
  • COG-APEC14B1: project: EveryChild - a registry, eligibility screening, biology and outcome study, Role: Investigator, Children Oncology Group, (08/2025 - 08/2026) Status: Approved
  • COG AALL1231: A phase III randomized trial investigating Bortezomib (NSC#681239; IND#58443) on a modified augmented BFM (ABFM) backbone in newly diagnosed T-Lymphoblastic Leukemia (T-ALL) and T-Lymphoblastic Lymphoma (T-LLy), Role: Investigator, Children Oncology Group, (01/2026 - 01/2027) Status: Approved
  • COG AAML1331: A phase III study for patients with newly diagnosed acute promyelocytic Leukemia (APL) using arsenic trioxide and all trans-retinoic acid, Role: Investigator, Children Oncology Group, (02/2026 - 02/2027) Status: Approved

For Profit Organization

  • P-CDI9CD20-ALLOI-001: Open-Label, Muticenter, Phase 1 Study to Assess the Safety of P-CDl9CD20-ALLO1 in Subjects with Selected Relapsed/Refractory B cell Malignancies, Role: PI, Poseida Therapeutics Inc., (12/2025 - 12/2026) Status: Approved
  • ATARA Biotherapeutics, Inc. ATA129-EBV-302: Multicenter, Open Label, Phase 3 study of Tabelecleucel for solid organ or allogeneic hematopoietic cell transplant subjects with Epstein-Barr virus-associated post-transplant lymphoproliferative disease after failure of Rituximab or Rituximab and Chemotherapy (ALLELE study), Role: Investigator, PIERRE FABRE MEDICAMENT, (11/2025 - 11/2026) Status: Approved
  • Juno Therapeutics JCAR017-EAP-001: Expanded access protocol (EAP) for subjects receiving Lisocabtagene Maraleucel that is nonconforming for commercial release., Role: PI, Celgene, Inc., (02/2026 - 02/2027) Status: Approved
  • Celgene BB2121-EAP-001: Expanded access protocol (EAP) for subjects receiving Idecabtagene vicleucel that is nonconforming for commercial Release, Role: PI, Celgene, Inc., (02/2026 - 02/2027) Status: Approved
  • ALLO-329-101: A Phase 1 Study, Evaluating the Safety and Preliminary Efficacy of ALLO-329, a Dual Anti-CD19/Anti-CD70 Allogenic Car T Cell in Autoimmune Disease, Role: PI, Allogene Therapeutics, Inc., (12/2025 - 12/2026) Status: Approved
  • CYTB323J12201: A Phase 2, Open-label, Study to Evaluate the Efficacy and Safety of Rapcabtagene Autoleucel in Patients Suffering with active, refractory Systemic Lupus Erythematosus (SLE) or Active, Refractory Lupus Nephritis (LN), Role: Investigator, Novartis Pharmaceuticals Corporation, (08/2025 - 08/2026) Status: Approved

Internal

  • Defibrotide prophylaxis in pediatric and adult hematopoietic stem cell transplant recipients: A Retrospective Chart Review (NYMC-217), Role: PI, LLU Dept. of Medicine, (07/2024) Status: Approved
  • LLU Cancer Center biospecimen laboratory - specimens collection protocol, Role: Investigator, LLU Cancer Center, (09/2025 - 09/2026) Status: Approved

Non-Profit Organization

  • The National Marrow donor Program (NMDP) and Center for International Blood and Marrow Transplant Research (CIBMTR) - Contribution of a Blood Sample to the National Marrow Donor Program's Research Sample Repository, Role: PI, National Marrow Donor Program, (09/2025 - 09/2026) Status: Approved
  • PTCTC ONC1701 (End RAD): A phase II pilot trial to estimate survival after a non-total body irradiation (TBI) based on conditioning regimen in patients diagnosed with B-acute lymphoblastic leukemia (ALL) who are pre-allogeneic hematopoietic cell transplantation (HCT) next-generation-sequence (NGS) minimal residual disease (MRD) negative, Role: PI, Pediatric Blood and Marrow Transplant Consortium, (05/2025 - 05/2026) Status: Approved
  • NMDP and CIBMTR - Protocol for Research Database for Hematopoietic Stem Cell Transplantation and Marrow Toxic Injuries., Role: PI, National Marrow Donor Program, (05/2025 - 05/2026) Status: Approved
  • National Marrow Donor Program® (NMDP) - 10-CBA: A multicenter access and distribution protocol for unlicensed cryopreserved cord blood units (CBUs) for transplantation in pediatric and adult patients with hematologic malignancies and other indications, Role: PI, National Marrow Donor Program, (08/2025 - 08/2026) Status: Approved
  • NMDP 17-SIBS: Identifying predictors of poor health-related quality-of-life among pediatric hematopoietic stem cell donors, Role: PI, National Marrow Donor Program, (06/2025) Status: Completed

State

  • Inland Empire and Desert Region CIRM Community Care Center of Excellence, Role: PD/PI, California Institute for Regenerative Medicine, (03/2026 - 02/2027) Status: Awarded